ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the ...
Masofaniten + enzalutamide well-tolerated, showing durable PSA reductions in mCRPC patients. Phase 2 expansion ongoing with 600 mg BID masofaniten + 160 mg QD enzalutamide. 88% achieved PSA90, 69% in <90 days, 63% PSA <0.2ng/mL. Median time to PSA/radiographic progression not yet reached after 15.2 months.
Related Clinical Trials
Reference News
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the ...
Masofaniten + enzalutamide well-tolerated, showing durable PSA reductions in mCRPC patients. Phase 2 expansion ongoing with 600 mg BID masofaniten + 160 mg QD enzalutamide. 88% achieved PSA90, 69% in <90 days, 63% PSA <0.2ng/mL. Median time to PSA/radiographic progression not yet reached after 15.2 months.